US20130225685A1 - Combination composition - Google Patents
Combination composition Download PDFInfo
- Publication number
- US20130225685A1 US20130225685A1 US13/882,953 US201113882953A US2013225685A1 US 20130225685 A1 US20130225685 A1 US 20130225685A1 US 201113882953 A US201113882953 A US 201113882953A US 2013225685 A1 US2013225685 A1 US 2013225685A1
- Authority
- US
- United States
- Prior art keywords
- approximately
- ibuprofen
- paracetamol
- combination
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 57
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 55
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229960005489 paracetamol Drugs 0.000 claims abstract description 55
- 238000001990 intravenous administration Methods 0.000 claims abstract description 17
- 206010061218 Inflammation Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GCCOJNYCFNSJII-VWMHFEHESA-N [n'-[(4s)-4-amino-4-carboxybutyl]carbamimidoyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 GCCOJNYCFNSJII-VWMHFEHESA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 2
- IHHXIUAEPKVVII-ZSCHJXSPSA-N [(1s)-5-amino-1-carboxypentyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCC[NH3+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 IHHXIUAEPKVVII-ZSCHJXSPSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- -1 pH modulators Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to a combination composition comprising paracetamol and ibuprofen.
- a particularly preferred embodiment of the invention relates to a combination composition containing these active ingredients for use in relieving pain and/or inflammation.
- Combinations of paracetamol and ibuprofen are known, for example as relatively low dose tablets having 150 mg ibuprofen and 500 mg paracetamol.
- a medication particularly one which can be administered intravenously in a hospital environment. It is an object of an embodiment of the present invention to go at least some way towards facilitating this.
- references in this specification to an adult mean a person weighing 50 kg or more.
- references in this specification to a child mean a person weighing less than 50 kg.
- ibuprofen and paracetamol are specifically referred to in this specification, suitable other pharmaceutically acceptable forms of these two actives (eg salts, etc) may also be used and are intended to be embraced in the claims by references to the actives per se, with the weight amounts adjusted accordingly.
- suitable other pharmaceutically acceptable forms of these two actives eg salts, etc
- sufficient quantity may be included to meet the desired amount of the compound per se (eg, 513 mg ibuprofen lysinate, or 553 mg ibuprofen arginine salt, corresponds with 300 mg ibuprofen).
- a reference to 300 mg ibuprofen may be construed as sufficient to embrace the therapeutically equivalent amount of ibuprofen lysinate or ibuprofen arginine.
- an intravenous composition for providing relief for pain and/or inflammation having ibuprofen and paracetamol in combination for delivering to a human at each dose:
- the composition is for dosing on approximately a 6 hourly basis.
- composition comprises:
- the composition is in the form of a solution.
- a further aspect of the invention comprises the use of paracetamol and ibuprofen in the manufacture of an intravenous medicament for treating pain and/or inflammation in a human wherein the medicament comprises, on a per dose basis:
- composition is for dosing on approximately a 6 hourly basis
- composition comprises:
- the composition is in the form of a solution.
- a further aspect of the invention comprises a method of treating pain and/or inflammation by administering to a human, intravenously, a medicament comprising:
- composition is administered on a 6 hourly basis.
- composition comprises:
- the composition is in the form of a solution.
- an intravenous solution for use in treating pain or inflammation in human patients.
- the solution is a combination medication comprising ibuprofen, paracetamol and suitable excipients as will be known to those with ordinary skills in the art of formulating intravenous medicines.
- the excipients may include suitable antioxidants, pH modulators, buffering agents isotonicity agents and purified water.
- Example 1 Ingredient mg/100 ml vial mg/100 ml vial Ibuprofen 150 300 Paracetamol 500 1,000
- the infusion solutions are for delivery to a patient as a full dose, for example in each case the patient receives the complete vial contents as a 15 minute infusion every 6 hours.
- Example 1 is a child's dose and Example 2 is an adult dose. In the case of very young or small children only part of the vial contents of Example 1 may be dosed on a body weight basis, commensurate with instructions from the prescribing physician.
- Paracetamol at 4,000 mg per 24 hour period taken in 4 doses of 1,000 mg every 6 hours, has long been considered sufficient for relieving low level pain but for many patients suffering significant pain, for example in some post operative situations, it is not sufficient. However it is generally not advisable to dose paracetamol at more than 1,000 mg per dose or at more than 4,000 mg per 24 hour period, because to do so can lead to undesirable side effects.
- ibuprofen It is known to treat severe pain with ibuprofen in doses of 800 mg every 8 hours. However. doses as high as 800 mg can lead to undesirable side effects, for example adverse cardio renal conditions, renal problems, thrombotic risks and gastrointestinal bleeding. Reducing the amount of ibuprofen at each dosing event may reduce the risk of side effects but at the same time may provide substantially less pain relief.
- an intravenous medicine comprising 150 mg or 300 mg ibuprofen, plus 500 mg or 1,000 mg paracetamol, respectively, for use every 6 hours, provides adequate pain relief for some patients that would otherwise need to take, respectively, 400 mg or 800 mg every 8 hours.
- the lower dose of ibuprofen reduces the risk of undesirable side effects in some patients but the effectiveness of the medication for such patients is not compromised due to the presence of the paracetamol. This is unexpected because for many patients one would not predict the presence of paracetamol to assist to any significant degree.
- the combination is counterintuitive because, for example, 400 mg ibuprofen for relief of pain is generally seen as an 8 hourly medicament, and 1,000 mg paracetamol is generally seen as a 6 hourly medicament.
- the normal dosage regimens for these active ingredients are out of step with one another, ie 8 hourly versus 6 hourly, and thus to the normally skilled artesian they would not, at the doses of the present invention, be seen as suitable for a combination medication.
- Administering an intravenous combination solution comprising 300 mg ibuprofen plus 1,000 mg paracetamol to an adult, or an intravenous combination solution comprising 150 mg ibuprofen plus 500 mg paracetamol to a child, on an ongoing basis, for example every 6 hours, provides a surprising level of pain relief compared to administering the same doses orally, for example by way of a tablet.
- the intravenous administration reduces the need for rescue pain relief in at least some patients recovering from surgical procedures.
- the intravenous administration may for example be by way of injection or infusion.
- the solution is for administration to an adult as a single intravenous dose and further equivalent doses may be repeated every 6 hours if need be, commensurate with instructions from the prescribing physician.
- AMOUNT ACTIVE INGREDIENTS Paracetamol 500 mg Ibuprofen arginine 276.5 mg EXCIPIENTS Reduced glutathione (as antioxidant) 10 mg Sodium hydroxide or hydrochloric sufficient to give a pH of 5-6 acid (as a pH modulator) Sodium citrate (as a buffering agent) 5 mg Sodium chloride (as an isotonicity sufficient to impart isotonicity agent) Purified water Sufficient to bring the composition to 100 ml
- the solution is for administration to a child as a single intravenous dose and further equivalent doses may be repeated every 6 hours if need be, commensurate with instructions from the prescribing physician.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ58901110 | 2010-11-04 | ||
| NZ589011 | 2010-11-04 | ||
| PCT/NZ2011/000226 WO2012060719A1 (en) | 2010-11-04 | 2011-10-26 | A combination composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/NZ2011/000226 A-371-Of-International WO2012060719A1 (en) | 2010-11-04 | 2011-10-26 | A combination composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/832,154 Continuation US20160235695A1 (en) | 2010-11-04 | 2015-08-21 | Combination composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20130225685A1 true US20130225685A1 (en) | 2013-08-29 |
Family
ID=46024668
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/882,953 Abandoned US20130225685A1 (en) | 2010-11-04 | 2011-10-26 | Combination composition |
| US14/832,154 Abandoned US20160235695A1 (en) | 2010-11-04 | 2015-08-21 | Combination composition |
| US16/149,109 Active US11446266B2 (en) | 2010-11-04 | 2018-10-01 | Combination composition |
| US17/943,708 Active US11896567B2 (en) | 2010-11-04 | 2022-09-13 | Combination composition |
| US18/405,907 Pending US20240207210A1 (en) | 2010-11-04 | 2024-01-05 | Combination composition |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/832,154 Abandoned US20160235695A1 (en) | 2010-11-04 | 2015-08-21 | Combination composition |
| US16/149,109 Active US11446266B2 (en) | 2010-11-04 | 2018-10-01 | Combination composition |
| US17/943,708 Active US11896567B2 (en) | 2010-11-04 | 2022-09-13 | Combination composition |
| US18/405,907 Pending US20240207210A1 (en) | 2010-11-04 | 2024-01-05 | Combination composition |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US20130225685A1 (ru) |
| EP (1) | EP2635269B1 (ru) |
| JP (2) | JP2013541583A (ru) |
| KR (1) | KR101900520B1 (ru) |
| CN (2) | CN103298464A (ru) |
| AU (1) | AU2011324137B2 (ru) |
| BR (1) | BR112013010829B8 (ru) |
| CA (1) | CA2814057C (ru) |
| CL (1) | CL2013001250A1 (ru) |
| CO (1) | CO6771406A2 (ru) |
| CY (1) | CY1123398T1 (ru) |
| DK (1) | DK2635269T3 (ru) |
| ES (1) | ES2742373T3 (ru) |
| HR (1) | HRP20191489T1 (ru) |
| HU (1) | HUE045442T2 (ru) |
| LT (1) | LT2635269T (ru) |
| MX (2) | MX367209B (ru) |
| MY (1) | MY160572A (ru) |
| NZ (1) | NZ609727A (ru) |
| PH (1) | PH12021550804A1 (ru) |
| PL (1) | PL2635269T3 (ru) |
| PT (1) | PT2635269T (ru) |
| RS (1) | RS59258B1 (ru) |
| RU (2) | RU2707089C2 (ru) |
| SG (1) | SG189319A1 (ru) |
| SI (1) | SI2635269T1 (ru) |
| WO (1) | WO2012060719A1 (ru) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016009067A1 (en) * | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
| WO2016057389A1 (en) * | 2014-10-06 | 2016-04-14 | Cumberland Pharmaceuticals, Inc. | Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain |
| WO2018193099A1 (en) | 2017-04-20 | 2018-10-25 | Hyloris Developments Sa | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
| US10376471B2 (en) | 2017-07-10 | 2019-08-13 | Gel Cap Technologies, LLC | Dual release dosage form capsule and methods, devices and systems for making same |
| US11568752B2 (en) * | 2020-01-28 | 2023-01-31 | David Clark Company Incorporated | Gateway retrieval alert device for aircraft pushback operations |
| US11806400B2 (en) | 2012-03-16 | 2023-11-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045442T2 (hu) | 2010-11-04 | 2019-12-30 | Aft Pharmaceuticals Ltd | Kombinációs készítmény |
| US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
| WO2023281089A2 (en) | 2021-07-08 | 2023-01-12 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising naproxen and paracetamol |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3990895A (en) * | 1995-12-05 | 1997-06-27 | Adcock Ingram Limited | Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic |
| ES2253326T3 (es) * | 2001-11-02 | 2006-06-01 | Cumberland Pharmaceuticals Inc. | Composicion farmaceutica de acido 2-(4-isobutilfenilo)propionico. |
| MXPA05010010A (es) * | 2003-03-21 | 2006-03-10 | Johnson & Johnson | Regimen de dosificacion de farmaco anti-inflamatorio no-esteroideo. |
| AU2005260243B2 (en) | 2004-07-07 | 2009-10-29 | Aft Pharmaceuticals Limited | A combination composition |
| KR20060072839A (ko) * | 2004-12-23 | 2006-06-28 | 김경태 | 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제 |
| US7934627B2 (en) * | 2005-10-13 | 2011-05-03 | Alcoa Inc. | Apparatus and method for high pressure extrusion with molten aluminum |
| EP2089013B1 (en) * | 2006-10-20 | 2017-09-27 | Johnson & Johnson Consumer Inc. | Combination of acetaminophen with ibuprofen for the treament of pain |
| WO2008079818A2 (en) * | 2006-12-21 | 2008-07-03 | Soluprin Pharmaceuticals, Inc. | Intravenous administration of water soluble analgesic formulations |
| KR20110112279A (ko) * | 2008-10-14 | 2011-10-12 | 에이에프티 파마슈티칼스 리미티드 | 의약품 및 치료 |
| KR20140014350A (ko) * | 2009-03-12 | 2014-02-06 | 큠버랜드 파마슈티컬즈 인코포레이티드 | 정맥 내 투여용 이부프로펜의 투여 |
| WO2012005605A1 (en) * | 2010-07-07 | 2012-01-12 | Aft Pharmaceuticals Limited | A combination composition comprising ibuprofen and paracetamol |
| HUE045442T2 (hu) | 2010-11-04 | 2019-12-30 | Aft Pharmaceuticals Ltd | Kombinációs készítmény |
| CA2963916A1 (en) * | 2014-10-06 | 2016-04-14 | Cumberland Pharmaceuticals, Inc. | Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain |
-
2011
- 2011-10-26 HU HUE11838295A patent/HUE045442T2/hu unknown
- 2011-10-26 RS RSP20190963 patent/RS59258B1/sr unknown
- 2011-10-26 EP EP11838295.1A patent/EP2635269B1/en active Active
- 2011-10-26 US US13/882,953 patent/US20130225685A1/en not_active Abandoned
- 2011-10-26 RU RU2015103107A patent/RU2707089C2/ru active
- 2011-10-26 PT PT11838295T patent/PT2635269T/pt unknown
- 2011-10-26 LT LTEP11838295.1T patent/LT2635269T/lt unknown
- 2011-10-26 MX MX2015008709A patent/MX367209B/es unknown
- 2011-10-26 NZ NZ609727A patent/NZ609727A/en unknown
- 2011-10-26 PL PL11838295T patent/PL2635269T3/pl unknown
- 2011-10-26 MX MX2013005113A patent/MX2013005113A/es not_active Application Discontinuation
- 2011-10-26 WO PCT/NZ2011/000226 patent/WO2012060719A1/en active Application Filing
- 2011-10-26 ES ES11838295T patent/ES2742373T3/es active Active
- 2011-10-26 CN CN2011800525659A patent/CN103298464A/zh active Pending
- 2011-10-26 CN CN201710623266.5A patent/CN107519159A/zh active Pending
- 2011-10-26 AU AU2011324137A patent/AU2011324137B2/en active Active
- 2011-10-26 CA CA2814057A patent/CA2814057C/en active Active
- 2011-10-26 SG SG2013026265A patent/SG189319A1/en unknown
- 2011-10-26 MY MYPI2013001237A patent/MY160572A/en unknown
- 2011-10-26 JP JP2013537631A patent/JP2013541583A/ja active Pending
- 2011-10-26 DK DK11838295.1T patent/DK2635269T3/da active
- 2011-10-26 KR KR1020137014178A patent/KR101900520B1/ko active IP Right Review Request
- 2011-10-26 RU RU2013123646/15A patent/RU2013123646A/ru not_active Application Discontinuation
- 2011-10-26 SI SI201131767T patent/SI2635269T1/sl unknown
- 2011-10-26 BR BR112013010829A patent/BR112013010829B8/pt active IP Right Grant
-
2013
- 2013-05-06 CL CL2013001250A patent/CL2013001250A1/es unknown
- 2013-05-22 CO CO13125952A patent/CO6771406A2/es not_active Application Discontinuation
-
2015
- 2015-08-21 US US14/832,154 patent/US20160235695A1/en not_active Abandoned
-
2017
- 2017-03-22 JP JP2017055893A patent/JP6353577B2/ja active Active
-
2018
- 2018-10-01 US US16/149,109 patent/US11446266B2/en active Active
-
2019
- 2019-07-18 CY CY20191100766T patent/CY1123398T1/el unknown
- 2019-08-16 HR HRP20191489 patent/HRP20191489T1/hr unknown
-
2021
- 2021-04-08 PH PH12021550804A patent/PH12021550804A1/en unknown
-
2022
- 2022-09-13 US US17/943,708 patent/US11896567B2/en active Active
-
2024
- 2024-01-05 US US18/405,907 patent/US20240207210A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
Non-Patent Citations (2)
| Title |
|---|
| Bookstaver et al, J Pain Res. 2010; 3: 67-79, Published online May 25, 2010 * |
| http://medical-dictionary.thefreedictionary.com/unit+dose, accessed on 05/17/2015. Copy is attached. * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11806400B2 (en) | 2012-03-16 | 2023-11-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| IL250112B (en) * | 2014-07-18 | 2022-10-01 | Everbright Pharmaceuticals S A R L | Aqueous composition containing paracetamol and ibuprofen |
| IL250112B2 (en) * | 2014-07-18 | 2023-02-01 | Everbright Pharmaceuticals S A R L | Aqueous composition containing paracetamol and ibuprofen |
| US11389416B2 (en) * | 2014-07-18 | 2022-07-19 | Hyloris Pharmaceuticals SA | Aqueous formulation comprising paracetamol and ibuprofen |
| US11219609B2 (en) * | 2014-07-18 | 2022-01-11 | Hyloris Pharmaceuticals SA | Aqueous formulation comprising paracetamol and ibuprofen |
| US20230181502A1 (en) * | 2014-07-18 | 2023-06-15 | Hyloris Pharmaceuticals SA | Aqueous formulation comprising paracetamol and ibuprofen |
| AU2015289035B2 (en) * | 2014-07-18 | 2020-03-26 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
| EA036212B1 (ru) * | 2014-07-18 | 2020-10-14 | Эвербрайт Фармасьютикалз С.А.Р.Л. | Водная композиция, содержащая парацетамол и ибупрофен, и способ ее получения |
| US11213498B2 (en) * | 2014-07-18 | 2022-01-04 | Hyloris Pharmaceuticals S.A. | Aqueous formulation comprising paracetamol and ibuprofen |
| US12083087B2 (en) * | 2014-07-18 | 2024-09-10 | Hyloris Pharmaceuticals SA | Aqueous formulation comprising paracetamol and ibuprofen |
| US20170209398A1 (en) * | 2014-07-18 | 2017-07-27 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
| WO2016009067A1 (en) * | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
| WO2016057389A1 (en) * | 2014-10-06 | 2016-04-14 | Cumberland Pharmaceuticals, Inc. | Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain |
| WO2018193099A1 (en) | 2017-04-20 | 2018-10-25 | Hyloris Developments Sa | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
| US11413241B2 (en) | 2017-04-20 | 2022-08-16 | Hyloris Developments Sa | Method for preparing a composition with a low dissolved oxygen content, comprising acetaminophen, and optionally one or more NSAIDs, and a composition obtained thereof |
| US10376471B2 (en) | 2017-07-10 | 2019-08-13 | Gel Cap Technologies, LLC | Dual release dosage form capsule and methods, devices and systems for making same |
| US20190307699A1 (en) * | 2017-07-10 | 2019-10-10 | Gel Cap Technologies, LLC | Dual release dosage form capsule and methods, devices and systems for making same |
| US11944707B2 (en) * | 2017-07-10 | 2024-04-02 | Gel Cap Technologies, LLC | Dual release dosage form capsule and methods, devices and systems for making same |
| US11568752B2 (en) * | 2020-01-28 | 2023-01-31 | David Clark Company Incorporated | Gateway retrieval alert device for aircraft pushback operations |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11896567B2 (en) | Combination composition | |
| JP2015510940A (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| US12042472B2 (en) | Sublingual epinephrine tablets | |
| US20110166234A1 (en) | Medicinal product and treatment | |
| AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
| CA2846340A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| CN110869003A (zh) | 一种不含防腐剂的固体剂型氨己烯酸药物组合物 | |
| AU2017305661B2 (en) | New use of N,N-bis-2-mercaptoethyl isophthalamide | |
| WO2012156502A2 (en) | Two component mouth rinse preparation | |
| US10265300B2 (en) | Methods of treating seizure disorders | |
| KR20170099911A (ko) | 파라세타몰 주사 제제 | |
| WO2020155507A1 (zh) | 一种不含防腐剂的固体剂型氨己烯酸药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: AFT PHARMACEUTICALS LIMITED, NEW ZEALAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATKINSON, HARTLEY C.;REEL/FRAME:030353/0071 Effective date: 20130422 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |